Related Experiment Videos

Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview

J Dingemanse¹, M Danhof, D D Breimer

¹Center for Bio-Pharmaceutical Sciences, State University of Leiden, Sylvius Laboratories, The Netherlands.

Pharmacology & Therapeutics

|January 1, 1988

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Evaluation of QTc Interval Prolongation With the Dual Endothelin Receptor Antagonist Aprocitentan.

Journal of cardiovascular pharmacology and therapeutics·2025

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.

CPT: pharmacometrics & systems pharmacology·2017

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.

Orphanet journal of rare diseases·2017

Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan.

Clinical pharmacokinetics·2015

Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension.

Journal of human hypertension·2014

Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2014

See all related articles